You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 283 No. 12, March 22, 2000 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (4)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA

Chronobiology of Recombinant Leptin Therapy

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Heymsfield and colleagues1 documented the effect of exogenous leptin administration on body weight and showed that only patients in the highest dose groups had significant weight loss compared with those taking placebo. We suggest that the physiological characteristics of leptin may be relevant to its pharmacokinetics.

Diurnal and ultradian oscillations are essential characteristics of hormone secretion. Leptin is characterized by nyctohemeral rhythms, with serum leptin concentrations being highest around midnight.2 This pattern closely resembles the circadian rhythmicity of other hormones, such as thyrotropin and prolactin, and precedes the peak concentrations of cortisol and growth hormone. To what extent the nocturnal increase in leptin is related to biological activity remains to be clarified. In humans, the nocturnal increase in leptin secretion seems to be entrained to meal timing and most likely is related to the cumulative hyperinsulinemia from food ingestion during the entire waking period.

Superimposed on . . . [Full Text of this Article]


RELATED ARTICLE

Recombinant Leptin for Weight Loss in Obese and Lean Adults: A Randomized, Controlled, Dose-Escalation Trial
Steven B. Heymsfield, Andrew S. Greenberg, Ken Fujioka, Russell M. Dixon, Robert Kushner, Thomas Hunt, John A. Lubina, Janet Patane, Barbara Self, Pam Hunt, and Mark McCamish
JAMA. 1999;282(16):1568-1575.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Rationale for the existence of additional adipostatic hormones
FRUHBECK and GOMEZ-AMBROSI
FASEB J. 2001;15:1996-2006.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.